286 related articles for article (PubMed ID: 21429576)
1. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.
Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H
Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576
[TBL] [Abstract][Full Text] [Related]
2. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid.
Hatakeyama H; Akita H; Kogure K; Oishi M; Nagasaki Y; Kihira Y; Ueno M; Kobayashi H; Kikuchi H; Harashima H
Gene Ther; 2007 Jan; 14(1):68-77. PubMed ID: 16915290
[TBL] [Abstract][Full Text] [Related]
4. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
5. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.
Hatakeyama H; Akita H; Harashima H
Adv Drug Deliv Rev; 2011 Mar; 63(3):152-60. PubMed ID: 20840859
[TBL] [Abstract][Full Text] [Related]
6. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
7. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
8. [Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid].
Hatakeyama H; Akita H; Kogure K; Harashima H
Yakugaku Zasshi; 2007 Oct; 127(10):1549-56. PubMed ID: 17917417
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation.
Akita H; Kogure K; Moriguchi R; Nakamura Y; Higashi T; Nakamura T; Serada S; Fujimoto M; Naka T; Futaki S; Harashima H
J Control Release; 2010 May; 143(3):311-7. PubMed ID: 20080139
[TBL] [Abstract][Full Text] [Related]
10. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
[TBL] [Abstract][Full Text] [Related]
11. Enhanced gene expression by a novel stearylated INF7 peptide derivative through fusion independent endosomal escape.
El-Sayed A; Masuda T; Khalil I; Akita H; Harashima H
J Control Release; 2009 Sep; 138(2):160-7. PubMed ID: 19465073
[TBL] [Abstract][Full Text] [Related]
12. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery.
Khalil IA; Hayashi Y; Mizuno R; Harashima H
J Control Release; 2011 Dec; 156(3):374-80. PubMed ID: 21864599
[TBL] [Abstract][Full Text] [Related]
13. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
14. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
16. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
17. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system.
Masuda T; Akita H; Nishio T; Niikura K; Kogure K; Ijiro K; Harashima H
Biomaterials; 2008 Feb; 29(6):709-23. PubMed ID: 18001828
[TBL] [Abstract][Full Text] [Related]
18. PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor.
Kim HJ; Oba M; Pittella F; Nomoto T; Cabral H; Matsumoto Y; Miyata K; Nishiyama N; Kataoka K
J Drug Target; 2012 Jan; 20(1):33-42. PubMed ID: 22066783
[TBL] [Abstract][Full Text] [Related]
19. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors.
Hatakeyama H; Akita H; Harashima H
Biol Pharm Bull; 2013; 36(6):892-9. PubMed ID: 23727912
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
